{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:33:18Z","timestamp":1790789598168,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"am","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.medmal.2020.09.005","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T18:55:53Z","timestamp":1601405753000},"page":"90-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors"],"prefix":"10.1016","volume":"51","author":[{"given":"A.","family":"Gaillet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Calin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Flandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Tubiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-A.","family":"Valantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Caumes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Katlama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pourcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2020.09.005_bib0085","series-title":"Global Tuberculosis Report","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.medmal.2020.09.005_bib0090","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2217\/fmb.15.9","article-title":"Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis","volume":"10","author":"Namale","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.medmal.2020.09.005_bib0095","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1473-3099(08)70184-1","article-title":"Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource limited settings","volume":"8","author":"Meintjes","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medmal.2020.09.005_bib0100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1086\/595985","article-title":"Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy","volume":"199","author":"Manabe","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.medmal.2020.09.005_bib0105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","article-title":"IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis","volume":"10","author":"M\u00fcller","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.medmal.2020.09.005_bib0110","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in Adult: 2018 recommendations of the international antiviral societ-USA panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.medmal.2020.09.005_bib0115","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"issue":"9936","key":"10.1016\/j.medmal.2020.09.005_bib0120","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 weeks results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2020.09.005_bib0125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0399-077X(98)80052-8","volume":"28","year":"1998","journal-title":"M\u00e9d Mal, Inf."},{"key":"10.1016\/j.medmal.2020.09.005_bib0130","first-page":"405","article-title":"Integrase strand transfer inhibitors and the emergence of immune reconstitution inflammatory syndrome (IRIS)","volume":"15","author":"Psichogiou","year":"2017","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.medmal.2020.09.005_bib0135","series-title":"Integrase inhibitors are an independent risk factor for IRIS; an ATHENA-Cohort study","author":"Wijting","year":"2017"},{"issue":"1","key":"10.1016\/j.medmal.2020.09.005_bib0140","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/QAI.0000000000001397","article-title":"Initiation of antiretroviral therapy containing integrase inhibitors increases the risk of IRIS requiring hospitalization","volume":"76","author":"Dutertre","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.medmal.2020.09.005_bib0145","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1473-3099(14)70711-X","article-title":"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, noncomparative, open-label, randomised trial","volume":"14","author":"Grinsztejn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medmal.2020.09.005_bib0150","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/COH.0000000000000445","article-title":"Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials","volume":"13","author":"Hill","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"10.1016\/j.medmal.2020.09.005_bib0155","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1615822","article-title":"Enhenced prophylaxis plus antiretroviral therapy for advanced HIV in Africa","volume":"377","author":"Hakim","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.medmal.2020.09.005_bib0160","doi-asserted-by":"crossref","first-page":"e1002706","DOI":"10.1371\/journal.pmed.1002706","article-title":"Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: a randomised controlled trial","volume":"15","author":"Kityo","year":"2018","journal-title":"PLoS Med"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X20307034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X20307034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:37:34Z","timestamp":1760078254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X20307034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0399077X20307034"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2020.09.005","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2020.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}